Eli Lilly and Novo Nordisk occupy leading positions in the obesity and diabetes markets, valued at more than $100 billion. Each of them has advantages, as well as dark spots in the pipeline of ...

Eli Lilly has linked lepodisiran to sustained reductions in a cardiovascular disease risk factor for nearly 1.5 years, bolstering the company’s argument that the siRNA candidate has an edge over ...

Eli Lilly and Company (NYSE: LLY) today announced positive Phase 2 results for lepodisiran, an investigational small interfering RNA (siRNA) therapy designed to lower the production of lipoprotein ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other billionaire Ken Fisher’s top growth stock picks. “Who am I to tell you anything ...

President Donald Trump said a deal to divest TikTok from its parent company to keep it accessible in the U.S. would be struck by the Saturday deadline. "We have a lot of potential buyers," Trump ...

Hims & Hers to sell Lilly's weight-loss drug on its telehealth platform Telehealth firm Hims & Hers Health said on Tuesday it plans to sell Eli Lilly's weight-loss drug, as it widens its offerings ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Eli Lilly has launched a new website-based access programme for some drugs like its new obesity therapy Zepbound, opening up a new direct-to-consumer (DTC) channel that could shake up how the ...

Eli Lilly has launched new single-dose 2.5mg and 5.0mg vials of its obesity drug Zepbound in a move that it said would make it easier for people paying for the drug out-of-pocket to afford treatment.

Eli Lilly (NYSE:LLY) is down 1% premarket and development partner Incyte (NASDAQ:INCY) is down 4%, both on light volume, on the... Investing.com - Here are the top five things you need to know in ...